Please login to the form below

Not currently logged in
Email:
Password:

renal disease

This page shows the latest renal disease news and features for those working in and with pharma, biotech and healthcare.

Merck’s Bavencio joins first-line kidney cancer face-off

Merck’s Bavencio joins first-line kidney cancer face-off

Merck KGaA and Pfizer have staked a claim to the first-line renal cell carcinoma market, with data on a new combination that analyst say could challenge to become a new ... The JAVELIN Renal 101 study reported at this week’s ESMO conference paired

Latest news

  • Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka

    include stage 4 within the ® licence follows the submission of extra data supporting its safety and efficacy in patients with more advanced renal disease. ... Jinarc  is the only drug treatment approved to slow the progression of cyst development and

  • Price matters Price matters

    And when patients cannot pay for their kidney transplants, or the waiting list for end-stage renal disease patients is so long that they die waiting for a transplant, they have

  • Amgen's chronic kidney disease drug Parsabiv cleared in US Amgen's chronic kidney disease drug Parsabiv cleared in US

    Amgen's chronic kidney disease drug Parsabiv cleared in US. Sensipar follow-up is the first therapy to be approved for treatment of sHPT in 12 years. ... However, some have warned that there could be pushback resulting from tighter reimbursement rules

  • Assisting adherence Assisting adherence

    At the same time, kidney transplantation is the treatment of choice for a growing number of patients with end-stage renal disease.

  • SMC approves Opdivo combo as first-line skin cancer treatment SMC approves Opdivo combo as first-line skin cancer treatment

    Amicus Therapeutics' Galafold (migalastat) has also received the go-ahead, and has been sanctioned by the SMC for the treatment of adults with Fabry disease, an incurable inherited genetic disorder. ... greater enzyme activity after evidence of renal,

More from news
Approximately 1 fully matching, plus 56 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Ionis has recently received a $75m milestone payment from Bayer having successfully completed a phase II study on IONIS-FXIRx in patients with end-stage renal disease on haemodialysis. ... Royalty monetisation. 150. BIAL/ Neurocrine Biosciences. ONGENTYS

  • Deal Watch November 2015 Deal Watch November 2015

    386. AstraZeneca. Perrigo. Acquisition - asset. Entocort (budesonide) marketed for mild to moderate Crohn's disease. ... Option to license. 175. Idera Pharmaceuticals. GlaxoSmithKline. Licence, collaboration. Antisence platform for selected targets in

  • The rising prevalence of diabetes in Europe The rising prevalence of diabetes in Europe

    Stroke: Risk is up to four times higher with diabetes. Cardiovascular disease: Risk is up to four times higher with diabetes. ... Diabetic nephropathy: This is the leading cause of end-stage renal disease.

  • Deal Watch table for February 2014 Deal Watch table for February 2014

    Company acquisition. Rare disease company with marketed products in US (Chenodal to treat CTX. ... 12. 1. Co-promotion rights in US. 2. Endstage renal disease. 3.

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    548. Cytori/Lorem. Vascular. Licence. Cell therapy for CVS, diabetes, and renal disease. ... 152. Calidus / Amicus. Acquisition. Purchase of Callidus' late-stage enzyme replacement therapy for Pompe disease.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics